Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction: effects on global left ventricular function
Daniel Sürder, Robert Manka, Viviana Lo Cicero, Tiziano Moccetti, Kaspar Rufibach, Sabrina Soncin, Lucia Turchetto, Marina Radrizzani, Giuseppe Astori, Juerg Schwitter, Paul Erne, Michel Zuber, Christoph Auf der Maur, Peiman Jamshidi, Oliver Gaemperli, Stephan Windecker, Aris Moschovitis, Andreas Wahl, Ines Bühler, Christophe Wyss, Sebastian Kozerke, Ulf Landmesser, Thomas F Lüscher, Roberto Corti, Daniel Sürder, Robert Manka, Viviana Lo Cicero, Tiziano Moccetti, Kaspar Rufibach, Sabrina Soncin, Lucia Turchetto, Marina Radrizzani, Giuseppe Astori, Juerg Schwitter, Paul Erne, Michel Zuber, Christoph Auf der Maur, Peiman Jamshidi, Oliver Gaemperli, Stephan Windecker, Aris Moschovitis, Andreas Wahl, Ines Bühler, Christophe Wyss, Sebastian Kozerke, Ulf Landmesser, Thomas F Lüscher, Roberto Corti
Abstract
Background: Intracoronary administration of autologous bone marrow-derived mononuclear cells (BM-MNC) may improve remodeling of the left ventricle (LV) after acute myocardial infarction. The optimal time point of administration of BM-MNC is still uncertain and has rarely been addressed prospectively in randomized clinical trials.
Methods and results: In a multicenter study, we randomized 200 patients with large, successfully reperfused ST-segment elevation myocardial infarction in a 1:1:1 pattern into an open-labeled control and 2 BM-MNC treatment groups. In the BM-MNC groups, cells were administered either early (i.e., 5 to 7 days) or late (i.e., 3 to 4 weeks) after acute myocardial infarction. Cardiac magnetic resonance imaging was performed at baseline and after 4 months. The primary end point was the change from baseline to 4 months in global LV ejection fraction between the 2 treatment groups and the control group. The absolute change in LV ejection fraction from baseline to 4 months was -0.4±8.8% (mean±SD; P=0.74 versus baseline) in the control group, 1.8±8.4% (P=0.12 versus baseline) in the early group, and 0.8±7.6% (P=0.45 versus baseline) in the late group. The treatment effect of BM-MNC as estimated by ANCOVA was 1.25 (95% confidence interval, -1.83 to 4.32; P=0.42) for the early therapy group and 0.55 (95% confidence interval, -2.61 to 3.71; P=0.73) for the late therapy group.
Conclusions: Among patients with ST-segment elevation myocardial infarction and LV dysfunction after successful reperfusion, intracoronary infusion of BM-MNC at either 5 to 7 days or 3 to 4 weeks after acute myocardial infarction did not improve LV function at 4-month follow-up.
Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00355186.
Keywords: bone marrow–derived progenitor cells; magnetic resonance imaging; myocardial infarction; regeneration; ventricular remodeling.
Source: PubMed